Unknown

Dataset Information

0

Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells.


ABSTRACT: Regulatory T cells (Tregs) expressing FOXP3 are essential for the maintenance of self-tolerance and are deficient in many common autoimmune diseases. Immune tolerance is maintained in part by IL-2 and deficiencies in the IL-2 pathway cause reduced Treg function and an increased risk of autoimmunity. Recent studies expanding Tregs in vivo with low-dose IL-2 achieved major clinical successes highlighting the potential to optimize this pleiotropic cytokine for inflammatory and autoimmune disease indications. Here we compare the clinically approved IL-2 molecule, Proleukin, with two engineered IL-2 molecules with long half-lives owing to their fusion in monovalent and bivalent stoichiometry to a non-FcR? binding human IgG1. Using nonhuman primates, we demonstrate that single ultra-low doses of IL-2 fusion proteins induce a prolonged state of in vivo activation that increases Tregs for an extended period of time similar to multiple-dose Proleukin. One of the common pleiotropic effects of high dose IL-2 treatment, eosinophilia, is eliminated at doses of the IL-2 fusion proteins that greatly expand Tregs. The long half-lives of the IL-2 fusion proteins facilitated a detailed characterization of an IL-2 dose response driving Treg expansion that correlates with increasingly sustained, suprathreshold pSTAT5a induction and subsequent sustained increases in the expression of CD25, FOXP3 and Ki-67 with retention of Treg-specific epigenetic signatures at FOXP3 and CTLA4.

SUBMITTER: Bell CJ 

PROVIDER: S-EPMC4298360 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications


Regulatory T cells (Tregs) expressing FOXP3 are essential for the maintenance of self-tolerance and are deficient in many common autoimmune diseases. Immune tolerance is maintained in part by IL-2 and deficiencies in the IL-2 pathway cause reduced Treg function and an increased risk of autoimmunity. Recent studies expanding Tregs in vivo with low-dose IL-2 achieved major clinical successes highlighting the potential to optimize this pleiotropic cytokine for inflammatory and autoimmune disease in  ...[more]

Similar Datasets

| S-EPMC3618592 | biostudies-literature
| S-EPMC10776352 | biostudies-literature
| S-EPMC6284106 | biostudies-literature
| S-EPMC7101153 | biostudies-literature
| S-EPMC7969576 | biostudies-literature
| S-EPMC2812540 | biostudies-literature
| S-EPMC3784339 | biostudies-literature
| S-EPMC9526546 | biostudies-literature
| S-EPMC3954945 | biostudies-literature
| S-EPMC3592793 | biostudies-literature